Aktie A3CQ56 DAY ONE BIOPHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Day One Biopharmaceuticals, Inc.

Aktien

A3CQ56

US23954D1090

DAWN

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 24.05.2024 		% 5 Tage % 1. Jan.
13,77 USD -0,72 % Intraday Chart für Day One Biopharmaceuticals, Inc. -14,84 % -5,68 %
20.05. BrightSpring Health Services gibt bekannt, dass Onco360 als Apothekenpartner für Ojemda ausgewählt wurde MT
07.05. DAY ONE BIOPHARMACEUTICALS, INC. : Bewertung von HC Wainwright zum Kaufen erhalten ZM

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
BrightSpring Health Services Says Onco360 Selected as Pharmacy Partner for Ojemda
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
North American Morning Briefing : Stock Futures -2-
Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing
Day One Biopharmaceuticals Insider Sold Shares Worth $1,415,707, According to a Recent SEC Filing
North American Morning Briefing : Investors Brace -2-
Day One Biopharmaceuticals : Corporate Presentation - April 2024
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma
Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment
Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval
Day One Biopharmaceuticals Insider Sold Shares Worth $322,166, According to a Recent SEC Filing
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
Day One Biopharmaceuticals, Inc. Announces Executive Changes
Day One Announces Two New Appointments to Board of Directors
Day One Biopharmaceuticals, Inc. Announces Board Appointments
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CQ56 Aktie
  4. Nachrichten Day One Biopharmaceuticals, Inc.
  5. Andere Sprachen